Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Rated 5 out of 5 Veronica T
Harmful LDL cholesterol increased in the group taking the higher dose of cilofexor (though it did not change in the lower-dose group), and triglycerides rose in the groups that used firsocostat
You should seek medical advice promptly if you: Are currently prescribed testosterone and are considering joining a retatrutide clinical trial Have noticed symptoms of hormonal imbalance such as fatigue, mood changes, reduced libido, or unexpected weight changes while on either treatment Have a history of polycythaemia, liver disease, prostate conditions, or cardiovascular disease, as these may affect suitability for either treatment Are sourcing retatrutide from unregulated online suppliers, which carries serious risks of counterfeit or contaminated products Seek urgent medical attention call 999 or use NHS 111 if you experience: Chest pain, palpitations, or breathlessness Severe, persistent upper abdominal pain (particularly if it radiates to the back), vomiting, or jaundice, which may indicate pancreatitis or gallbladder disease For those already on testosterone therapy through the NHS or a regulated private provider, it is important to inform your prescribing clinician of any new treatments including investigational drugs so that monitoring plans can be adjusted accordingly
Key findings from early trials include: Sustained weight loss over nearly one year of treatment Improvements in blood sugar control, with many participants achieving normal HbA1c levels Reduced liver fat content, beneficial for metabolic health Generally well-tolerated side effect profile These results represent some of the most substantial weight loss outcomes observed in clinical trials for obesity medications
